SK-N-SH Cell Line
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">SK-N-SH Cell Line</th>
</tr>
<tr>
<td class="label">Organism</td>
<td>Homo sapiens (human)</td>
</tr>
<tr>
<td class="label">Age</td>
<td>4 years</td>
</tr>
<tr>
<td class="label">Gender</td>
<td>Female</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Neuroblastoma</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Brain</td>
</tr>
<tr>
<td class="label">Metastatic site</td>
<td>Bone marrow</td>
</tr>
<tr>
<td class="label">Growth properties</td>
<td>Adherent</td>
</tr>
<tr>
<td class="label">Morphology</td>
<td>Epithelial (S-type) / Neuronal (N-type)</td>
</tr>
<tr>
<td class="label">Karyotype</td>
<td>Hyperdiploid human female (XX), modal chromosome number 47, trisomic for N7</td>
</tr>
<tr>
<td class="label">Biosafety Level</td>
<td>BSL 1</td>
</tr>
<tr>
<td class="label">Medium</td>
<td>Eagle's Minimum Essential Medium (EMEM) + 10% FBS</td>
</tr>
<tr>
<td class="label">Temperature</td>
<td>37°C</td>
</tr>
<tr>
<td class="label">Doubling time</td>
<td>~48 hours</td>
</tr>
<tr>
<td class="label">Cell Line</td>
<td>ATCC</td>
</tr>
<tr>
<td class="label">SH-SY5Y</td>
<td>CRL-2266</td>
</tr>
<tr>
<td class="label">SK-N-MC</td>
<td>HTB-10</td>
</tr>
<tr>
<td class="label">IMR-32</td>
<td>CCL-127</td>
</tr>
<tr>
<td class="label">M17</td>
<td>—</td>
</tr>
<tr>
<td class="label">LUHMES</td>
<td>—</td>
</tr>
<tr>
<td class="label">PC12</td>
<td>CRL-1721</td>
</tr>
</table>
Overview
SK-N-SH (ATCC HTB-11) is a human neuroblastoma cell line widely used in neurobiology and neurodegeneration research. Established from a bone marrow metastasis in a 4-year-old female patient in 1970, this cell line serves as a valuable in vitro model for studying neuronal differentiation, neurotoxicity, and therapeutic interventions for neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD)[@biedler1973][@ciccarone1989].
The cell line exhibits a unique bipotential nature, with cells capable of existing in either a neuronal (N-type) or substrate-adherent (S-type) morphology. This heterogeneity reflects the developmental plasticity of neural crest-derived cells and has made SK-N-SH a valuable model for studying cellular differentiation and lineage commitment[@ross1983].
Basic Characteristics
Origin and History
The SK-N-SH cell line was developed by J.L. Biedler and colleagues at the Memorial Sloan Kettering Cancer Center[@biedler1973]. The cell line was deposited by G. Trempe and L.J. Old and accessioned into the ATCC collection as HTB-11.
SK-N-SH differs from related neuroblastoma lines (such as SK-N-MC, ATCC HTB-10) in several key aspects:
- Longer population doubling time
- Higher levels of dopamine-beta-hydroxylase (DBH) expression
- Greater capacity for neuronal differentiation
- More pronounced catecholamine metabolism
The cell line represents a committed neuronal lineage derived from the neural crest, explaining its ability to produce neurotransmitters and express neuronal markers[@ciccarone1989][@ross1983].
Cellular and Molecular Characteristics
Morphological Variants
SK-N-SH cells exist in two main morphological forms:
N-type (neuronal) cells:
- Small, round cell bodies with short neurite-like extensions
- Higher expression of neuronal markers
- Capable of electrical excitability
- More relevant for neuronal studies
S-type (substrate-adherent) cells:
- Larger, flat cells with extensive cytoplasmic spread
- Strong adhesion to tissue culture substrate
- Less neuronal in character
- May represent a more proliferative state
The ratio of N-type to S-type cells can be modulated by culture conditions and differentiation agents[@ross1983].
Marker Expression
Key neuronal markers expressed in SK-N-SH include:
Cytoskeletal proteins:
- Neurofilament proteins (NF-L, NF-M, NF-H)
- MAP2 (Microtubule-associated protein 2)
- [Tau protein](/proteins/tau)
Enzymes and metabolic markers:
- Neuron-specific enolase (NSE)
- Tyrosine hydroxylase (TH) — rate-limiting enzyme in dopamine synthesis
- [Dopamine](/mechanisms/dopaminergic-signaling)beta-hydroxylase (DBH)
- Glutamate decarboxylase (GAD)
- Choline acetyltransferase (ChAT)
Synaptic markers:
- Synaptophysin
- Synapsin I
- PSD-95
Surface receptors:
- TrkA (nerve growth factor receptor)
- TrkB (BDNF receptor)
- Dopamine transporter (DAT)
- NMDA and AMPA glutamate receptors[@cheng2002]
Neurotransmitter Systems
SK-N-SH cells possess functional neurotransmitter systems:
Dopaminergic properties:
- Express tyrosine hydroxylase (TH) and can synthesize L-DOPA
- Express dopamine-beta-hydroxylase (DBH) for conversion to norepinephrine
- Possess functional dopamine transporter (DAT)
- Capable of dopamine release upon depolarization[@cheng2002]
GABAergic properties:
- Express glutamate decarboxylase (GAD)
- Synthesize and release GABA
- GABA-A receptor functional
Cholinergic properties:
- Express choline acetyltransferase (ChAT)
- Capable of [acetylcholine](/entities/acetylcholine) synthesis
Differentiation Protocols
SK-N-SH cells can be differentiated toward a more mature neuronal phenotype using various agents. Differentiated cells show enhanced neuronal characteristics and are more relevant for studying age-related neurodegeneration[@phlman1991].
Retinoic Acid Differentiation
All-trans retinoic acid (RA) is the most commonly used differentiation agent:
Protocol:
- RA concentration: 10 μM
- Duration: 5-7 days
- Medium change: Every 2 days
Results:
- Extension of long, branching neurites
- Increased expression of neuronal markers (MAP2, neurofilament)
- Enhanced neurotransmitter synthesis
- Reduced proliferation rate
- Electrophysiological maturation[@phlman1991][@encinas2000]
Mechanism: RA acts through nuclear retinoic acid receptors (RARs) to regulate gene expression programs involved in neuronal differentiation.
BDNF-Induced Differentiation
Brain-derived neurotrophic factor promotes neuronal differentiation and survival:
Protocol:
- BDNF concentration: 50-100 ng/mL
- Duration: 3-5 days
- Often combined with RA pretreatment
Results:
- Enhanced neurite outgrowth
- Increased neuronal marker expression
- Improved neuronal survival
- Synapse formation[@encinas2000]
Sequential Differentiation (RA + BDNF)
A two-stage protocol produces more mature [neurons](/entities/neurons):
Stage 1 (Days 1-5):
- 10 μM all-trans retinoic acid
- Promotes initial neuronal differentiation
Stage 2 (Days 6-10):
- Remove RA, add BDNF (50 ng/mL)
- Promotes maturation and survival
This protocol yields cells with more elaborate neurite networks and higher expression of synaptic markers[@encinas2000].
cAMP Differentiation
Elevated intracellular cAMP drives neuronal differentiation:
Protocol:
- Forskolin (10 μM) + IBMX (50 μM), or
- Dibutyryl-cAMP (1 mM)
- Duration: 2-5 days
Results:
- Morphological changes toward neuronal phenotype
- Increased neuronal marker expression
- Enhanced neurotransmitter release[@scheibe1986]
Phorbol Ester Differentiation
Phorbol 12-myristate 13-acetate (PMA) activates PKC:
Protocol:
- PMA concentration: 10-50 nM
- Duration: 3-5 days
Results:
- Neurite outgrowth
- Expression of neuronal markers
- Note: PKC activation may have complex effects on signaling pathways
Applications in Alzheimer's Disease Research
SK-N-SH cells have been extensively used as an in vitro model for studying Alzheimer's disease mechanisms[@yao2011]:
Amyloid-beta Toxicity Studies
- [Aβ](/proteins/amyloid-beta)-induced oxidative stress: SK-N-SH cells exposed to Aβ peptides show increased [ROS](/entities/reactive-oxygen-species) production, lipid peroxidation, and mitochondrial dysfunction[@yao2011]
- Neuroinflammation: Treatment with Aβ increases M-CSF (macrophage colony-stimulating factor) and other inflammatory mediators
- Synaptic dysfunction: Aβ exposure affects synaptic marker expression and function
- [Autophagy](/entities/autophagy) studies: Aβ triggers autophagy dysregulation in these cells
Tau Pathology Models
- Hyperphosphorylated tau expression: Transfection with mutant tau constructs
- Tau aggregation: Studies on tau oligomerization and fibrillization
- Tau-mediated toxicity: Investigation of tau-induced neuronal death pathways
- Therapeutic screening: Testing anti-tau compounds for efficacy[@chen2013]
Neurotrophin Signaling
SK-N-SH express Trk receptors and are used to study:
- BDNF/TrkB signaling in neuronal survival and plasticity
- APP processing and [amyloid precursor protein](/entities/app-protein) metabolism
- Effects of AD-associated mutations (APP, [PSEN1](/entities/psen1), PSEN2) on cellular function
- [NMDA receptor](/entities/nmda-receptor) function and excitotoxicity
Pharmaceutical and academic researchers use SK-N-SH for:
- Anti-amyloid compounds: Screening for Aβ-lowering or Aβ-protective agents
- Neuroprotective agents: Compounds that protect against Aβ toxicity
- Antioxidants: Testing compounds that counteract oxidative stress
- Anti-tau therapies: Small molecules and antibodies targeting tau pathology
- Repurposing screens: FDA-approved drugs for potential AD treatment[@chen2013]
Limitations in AD Research
- Tumor-derived cells may not fully recapitulate primary neurons
- Lack of tau pathology in vivo context
- Cannot model complex glia-neuron interactions
- Missing [blood-brain barrier](/entities/blood-brain-barrier)
Applications in Parkinson's Disease Research
SK-N-SH cells serve as a valuable model for PD research, particularly for dopaminergic neuron biology[@xie2010]:
Dopaminergic Differentiation
SK-N-SH can be differentiated toward a dopaminergic phenotype:
- Expression of TH, DAT, and AADC
- Dopamine synthesis and release upon stimulation
- Metabolic studies of dopaminergic neurons
- Development studies of midbrain dopaminergic lineages
Alpha-Synuclein Studies
The cell line is used to model Lewy body pathology:
- Wild-type SNCA overexpression: Aggregation and toxicity studies
- Mutant [alpha-synuclein](/proteins/alpha-synuclein): A30P, E46K, A53T mutations
- Oligomerization mechanisms: How wild-type and mutant proteins form oligomers
- Transmission studies: Cell-to-cell propagation of alpha-synuclein[@da2022]
- Therapeutic screening: Compounds that prevent aggregation or enhance clearance
Neurotoxin Models
PD-relevant neurotoxins are used to model dopaminergic degeneration:
MPP+ (1-methyl-4-phenylpyridinium):
- Active metabolite of MPTP
- Inhibits mitochondrial complex I
- Induces selective dopaminergic degeneration
- Used to study mitochondrial dysfunction in PD[@xie2010]
6-Hydroxydopamine (6-OHDA):
- Oxidative stress inducer
- Selective for catecholaminergic neurons
- Causes rapid dopaminergic degeneration
- Used for neuroprotective compound screening
Rotenone:
- Natural mitochondrial complex I inhibitor
- Produces PD-like pathology in animals
- Used in vitro to model mitochondrial dysfunction
LRRK2 Research
SK-N-SH expressing mutant [LRRK2](/entities/lrrk2) are used to study:
- LRRK2 kinase activity and substrate phosphorylation
- Pathogenic mutations: G2019S, R1441C/G, I2020T
- LRRK2 inhibitors: Kinase inhibitors for therapeutic development
- Alpha-synuclein interaction: How LRRK2 affects synucleinopathy[@cookson2010]
Limitations in PD Research
- Not true midbrain dopaminergic neurons
- Lacks the substantia nigra microenvironment
- Cannot fully model chronic progressive neurodegeneration
- Missing neuromelanin synthesis
Genetic Manipulation
SK-N-SH cells are readily amenable to genetic manipulation:
Transfection
- Plasmid transfection: Lipofection, calcium phosphate, electroporation
- Stable cell lines: G418, puromycin, hygromycin selection
- Transient expression: For rapid functional studies
Viral Vectors
- Lentivirus: For stable integration and difficult-to-transfect genes
- Adenovirus: High-efficiency transient expression
- AAV: For long-term gene expression
CRISPR/Cas9 Gene Editing
- Knockout: Target genes of interest
- Knockin: Insert disease-associated mutations
- CRISPRi/a: Transcriptional activation or repression
RNAi Technologies
- siRNA: Transient knockdown
- shRNA: Stable knockdown via lentiviral vectors
- CRISPRi: Catalytically dead Cas9 for gene repression
Limitations and Considerations
Tumor origin: Derived from neuroblastoma, may not fully represent normal neurons
Heterogeneity: Mixed N-type/S-type population can complicate experiments
Limited maturation: Differentiated cells are not fully mature neurons
Genetic drift: Long-term culture can lead to phenotypic changes
Species context: Human cells, but lacking brain microenvironment
Absence of glia: Cannot model neuron-glia interactions
Missing blood-brain barrier: Not representative of CNS in vivo contextDespite these limitations, SK-N-SH remains a valuable and widely-used model system for initial studies and drug screening before validation in more complex systems.
See Also
- [SH-SY5Y](/cell-types/sh-sy5y)
- [IMR-32](/cell-types/imr-32)
- [Alzheimer's Disease Cell Models](/diseases/alzheimers-disease)
- [Parkinson's Disease Cell Models](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)